Dexmedetomidine Hydrochloride
| Evidence Level: L5 | Predicted Indications: 50 |
Quick Overview
| Item | Value |
|---|---|
| Drug Name | Dexmedetomidine Hydrochloride |
| DrugBank ID | DB00633 |
| Brand Names (EU) | Dexdor |
| Evidence Level | L5 |
| Predicted Indications | 50 |
| Top Prediction Score | 99.60% |
Approved Indication (EMA)
For sedation of adult intensive care unit patients requiring a sedation level not deeper than arousal in response to verbal stimulation (corresponding to Richmond Agitation-Sedation Scale (RASS) 0 to -3).
Predicted New Indications
TxGNN model predictions for potential drug repurposing:
| Rank | Indication | Score | Source |
|---|---|---|---|
| 1 | nephrogenic syndrome of inappropriate antidiuresis | 99.60% | DL |
| 2 | migraine disorder | 99.49% | DL |
| 3 | migraine with brainstem aura | 99.35% | DL |
| 4 | headache disorder | 99.30% | DL |
| 5 | trigeminal autonomic cephalalgia | 99.09% | DL |
| 6 | pulmonary hypertension | 98.40% | DL |
| 7 | hypotrichosis simplex of the scalp | 98.35% | DL |
| 8 | migraine with or without aura, susceptibility to | 98.27% | DL |
| 9 | atrophoderma vermiculata | 98.26% | DL |
| 10 | congenital hypotrichosis milia | 98.24% | DL |
| 11 | diffuse alopecia areata | 98.14% | DL |
| 12 | ulerythema ophryogenesis | 98.04% | DL |
| 13 | alopecia | 97.91% | DL |
| 14 | kyphoscoliotic heart disease | 97.79% | DL |
| 15 | Tourette syndrome | 97.69% | DL |
| 16 | open-angle glaucoma | 97.66% | DL |
| 17 | primary hereditary glaucoma | 97.65% | DL |
| 18 | bronchial disease | 97.49% | DL |
| 19 | trichotillomania | 97.43% | DL |
| 20 | tendinitis | 97.20% | DL |
Showing top 20 of 50 predictions.
About TxGNN Predictions
Prediction Sources
| Source | Description |
|---|---|
| KG | Knowledge Graph - Network topology-based associations |
| DL | Deep Learning - Neural network score prediction |
Evidence Levels
| Level | Definition |
|---|---|
| L1 | Multiple Phase 3 RCTs / Systematic Reviews |
| L2 | Single RCT or multiple Phase 2 trials |
| L3 | Observational studies / Large case series |
| L4 | Preclinical / Mechanistic / Case reports |
| L5 | AI prediction only (current) |
Clinical Validation Needed
Research Use Only: These predictions are computational hypotheses that require clinical validation. They should NOT be used for clinical decision-making.
Next Steps for Validation
- Literature Review: Search PubMed for existing evidence
- Clinical Trial Search: Check ClinicalTrials.gov for ongoing studies
- Mechanistic Analysis: Evaluate biological plausibility
- Preclinical Studies: Conduct in vitro/in vivo validation
- Clinical Trials: Design and conduct human studies
Data Access
- FHIR API:
/fhir/ClinicalUseDefinition/ - CSV Download: All Predictions
- GitHub: yao-care/EuTxGNN
Citation
If using this data, please cite:
@article{huang2023txgnn,
title={A foundation model for clinician-centered drug repurposing},
author={Huang, Kexin and others},
journal={Nature Medicine},
year={2023},
doi={10.1038/s41591-023-02233-x}
}
Disclaimer: This report is for research purposes only and does not constitute medical advice. Drug repurposing predictions require rigorous clinical validation before any therapeutic application.